UNSPSC 51332843: Chlorpromazine phenolphthalinate

This classification denotes a phenothiazine and antipsychotic agent C20H16O4.C17H19ClN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5PYC320IMD, chemically known as benzoic acid, 2-(bis(4-hydroxyphenyl)methyl)-, compd. with 2-chloro-n,n-dimethyl-10h-phenothiazine-10-propanamine (1:1), but more generally known as chlorpromazine phenolphthalinate, which bears US NIH Compound Identifier 2726. Most nations, for tariff and trade purposes, schedule chlorpromazine phenolphthalinate under HS 29343090 and SITC 51578.

As of Q4 2014, CHLORPROMAZINE PHENOLPHTHALINATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCCN1C2CCCCC2SC3C1CC(CC3)CL.C1CCC(C(C1)C(C2CCC(CC2)O)C3CCC(CC3)O)C(=O)O.

UNSPSC 51332843 Chlorpromazine phenolphthalinate is a Commodity code that shows limited direct alignment with recent state and local procurement activity. The code nominally covers a specific pharmaceutical compound, but the single recent opportunity posted under this code—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and safe drug deactivation systems for community health initiatives, a scope that diverges from the code's stated pharmaceutical substance. This mismatch suggests either a tagging error in the county's procurement system or that the code is used only sporadically for health-related pharmaceutical and medical device procurement.

Seminole County, Florida issued the sole recent opportunity on June 30, 2026, with a response deadline of July 26, 2023—an inconsistency in the source dates that raises questions about the currency of the record. The solicitation calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The procurement is structured as a competitive IFB with a two-year initial term and one-year renewal option, fixed-fee pricing, and potential FEMA funding with associated federal compliance requirements. Vendors must comply with E-Verify, drug-free workplace certification, and standard insurance requirements, with a three-month probationary termination clause. Because only one recent opportunity appears in the source and it represents a product category only loosely related to the code's pharmaceutical focus, this code shows minimal relevant activity for state and local business development purposes.